Trials / Completed
CompletedNCT05546957
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
A Parallel Group Study in Healthy Participants to Quantify Subclinical Gastrointestinal Blood Loss Following Administration of Aspirin Alone or Aspirin in Combination With Rivaroxaban
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay. The secondary objective of the study is to evaluate the safety and tolerability of aspirin alone or in combination with rivaroxaban to healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin | Administered orally once per day (QD) |
| DRUG | rivaroxaban low dose | Administered orally twice per day (BID) |
| DRUG | rivaroxaban high dose | Administered orally QD |
Timeline
- Start date
- 2023-01-05
- Primary completion
- 2023-04-06
- Completion
- 2023-04-06
- First posted
- 2022-09-21
- Last updated
- 2023-05-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05546957. Inclusion in this directory is not an endorsement.